EXPERIMENTAL TREATMENT OF HUMAN HODGKINS-DISEASE WITH RICIN A-CHAIN IMMUNOTOXINS

被引：15

作者：

ENGERT, A

GOTTSTEIN, C

WINKLER, U

AMLOT, P

PILERI, S

DIEHL, V

THORPE, P

机构：

[1] Med. Universitatsklinik I.

[2] Department of Immunology, The Royal Free Hospital, London NW3, Pond Street

[3] Instituto di Ematologia 1, Servicio di Anatomia Pathologica, Universita di Bologna, Bologna

[4] Cancer Immunobiology Center, The University of Texas, Southwestern Medical Center, Dallas, TX

来源：

LEUKEMIA & LYMPHOMA | 1994年 / 13卷 / 5-6期

关键词：

TREATMENT; RICIN-A CHAIN; IMMUNOTOXIN; HODGKINS DISEASE;

D O I：

10.3109/10428199409049633

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In the present paper we describe the evaluation of ricin A-chain immunotoxins for clinical application in Hodgkin's disease. The immunotoxins were constructed by chemically linking deglycosylated ricin-A to monoclonal antibodies (MoAb) recognising lymphocyte activation markers CD25, CD30, or IRac, which are expressed by Hodgkin's and Reed-Sternberg (HRS) cells. The cytotoxic effects of the immunotoxins were investigated in vitro against L540Cy Hodgkin cells and in vivo against Hodgkin's tumors in nude mice and disseminated Hodgkin's tumors in SCID mice. MoAbs were evaluated for crossreactivity with normal human tissues and staining of sections from Hodgkin's disease tissue. Of 32 MoAbs, eight showed little crossreactivity with vital human organs and produced highly active immunotoxins. The most effective immunotoxin, RFT5 gamma l.dgA (CD25), inhibits the growth of H-RS cells at concentrations of 7 x 10(-12) M. RFT5 gamma l.dgA destroys about 60% of solid Hodgkin's tumors of 0.5 cm diameter in nude mice and induces complete remissions in 95% of SCID mice with disseminated Hodgkin's tumors when administered one day after tumor challenge. This immunotoxin binds to all H-RS cells in more than 90% of patients with Hodgkin's disease. Patients with refractory Hodgkin's disease are currently being treated in a phase-I/II clinical trial.

引用

页码：441 / 448

页数：8

共 25 条

[1]

Vitetta E.S., Stone M., Amlot P., Fay J., Till M., Uhr J.W., Redesigning nature's poisons to create antitumor agents, Science, 238, pp. 1098-1104, (1987)

[2]

Fitz Gerald D., Pastan I., Targeted toxin therapy for the treatment of cancer, J. Natl. Cancer Inst., 81, pp. 1455-1462, (1989)

[3]

Ghetie M.A., Richardson J., Tucker T., Jones D., Uhr J., Vitetta E., Antitumor activity of Fab' and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: Effect on tumor cells in extranodal sites, Cancer Res., 51, pp. 5860-5876, (1991)

[4]

Jansen B., Vallera D., Jaszcz W., Nguyen D., Kersey J., Successful treatment of human acute T-cell leukemia in SCID mice using the anti-CD7-deglycosylated ricin A-chain immunotoxin DA7, Cancer Res., 52, (1992)

[5]

Thorpe P.E., Detre S.I., Foxwell B.M.J., Brown A.N.F., Skilleter D.N., Wilson G., Forrester J.A., Stirpe F., Modification of the carbohydrate in ricin with me-taperiodate-cyanoborohydride mixtures. Effect on toxicity and in vivo distribution, Eur. J. Biochem., 147, (1985)

[6]

Blakey D.C., Watson G., Knowles P.P., Thorpe P.E., Effect of chemical deglycosilation of ricin A-chain on the in vivo fate and cytotoxic activity of an immunotoxin composed of ricin A-chain and anti-Thy 1.1 antibody, Cancer Res., 47, pp. 947-952, (1987)

[7]

Thorpe P.E., Wallace P.M., Knowles P.P., Relf M.G., Brown A.N.F., Watson G.J., Knyba R.E., Wawrzyn-Czak E.J., Blakey D.C., New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo, Cancer Res., 47, pp. 5924-5931, (1987)

[8]

Thorpe P.E., Wallace P.M., Knowles P.P., Relf M.G., Brown A.N.F., Watson G.J., Blakey D.C., Newell D., Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disul fide linkages, Cancer Res., 48, (1988)

[9]

Knowles P.P., Thorpe P.E., Purification of immunotoxins containing ricin A-chain and abrin A-chain using Blue Sepharose CL-6B, Anal. Biochem., 160, pp. 440-443, (1987)

[10]

Kaplan H.S., Hodgkin's disease: unfolding concepts concerning its nature, management and prognosis, Cancer, 45, (1980)

← 1 2 3 →